Skip to main content
European Commission logo print header

A High-throughput, Functional Imaging Platform to Accelerate Drug Discovery

Project description

Novel platform at the service of drug discovery for brain disease

Most techniques for functional imaging either interfere with cellular viability and physiology or provide poor resolution. To address these limitations, scientists of the EU-funded Ima-Go project have investigated the commercial feasibility of a 96-well platform that is label-free, non-invasive and can be used with live human cells for high-quality readouts. The platform uses electrodes to track neuronal activity, offering a novel solution for pharmaceutical companies interested in drug development for brain diseases. The Ima-Go project will further scale this technology to a high-throughput platform required in the drug discovery pipeline and introduce novel biological assays that cannot be performed by current competing technologies.


The aim of this SME Instruments Phase 1 proposal is to perform a feasibility study for the commercialization of Ima-Go, a novel 96-well functional imaging platform for preclinical drug discovery for substances targeting brain diseases.
In contrast to state-of-the-art technologies for functional imaging, which either interfere with cellular viability and physiology or provide only a poor spatiotemporal resolution, Ima-Go is label-free, non-invasive and provides readouts of highest quality and resolution. The Ima-Go platform will introduce to the market new biological assays for human cell lines, which cannot be performed by current competing technologies.

MaxWell Biosystems AG developed the most advanced functional imaging platform for tracking neuronal activity used in basic neuroscience research. With Ima-Go, MaxWell Biosystem will scale this technology to a throughput required in drug discovery applications. MaxWell Biosystems AG aims to become a world-wide technology leader in the field of advanced functional imaging platforms and modern data analysis solutions, meeting the needs of pharmaceutical companies and contract research organizations to accelerate drug development.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
8047 Zurich

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00